Amoy Diagnostics (300685.SZ) announced that the company's self-developed FGFR2 gene breakpoint detection kit (fluorescence in situ hybridization method) has recently been approved for marketing by the Ministry of Health, Labor and Welfare of Japan. This product has high sensitivity, strong specificity, and good accuracy. The dual-color breakpoint probe design can accurately identify and detect FGFR2 fusion, serving as a companion diagnostic reagent for the innovative targeted drug Tasurgratinib in the field of healthcare materials.